VIVUS Inc

VIVUS — Technical Presentation (October 2009)

27 slides from VIVUS's technical presentation, Oct 26, 2009

  1. Slide 1: Qnexa Pharmacotherapy Update

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com Qnexa Pharmacotherapy Update October 24, 2009 Wesley W. Day VP Clinical Development VIVUS Inc.

  2. Slide 2: Qnexa: Proprietary Investigational Treatment for Obesity

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com 400 mg Qnexa: Proprietary Investigational Treatment for Obesity • Once-a-day, oral, controlled-release formulation of low dose phentermine and topiramate • Specifically designed to impact normal eating patterns over 24 hours - simultan

  3. Slide 3: EQUIP & CONQUER Study Designs: Primary Study Endpoints

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER Study Designs: Primary Study Endpoints Co-Primary Endpoints (at 1 year) • Mean percent weight loss • The difference in mean percent loss of baseline body weight in the active-product versus placebo-treated group • Categ

  4. Slide 4: EQUIP & CONQUER: Study Entry Criteria

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Study Entry Criteria • Adults <70 years of age • BMI >35 • Blood pressure <140/90 mmHg using 0-2 antihypertensive medications • Fasting blood glucose < 110 mg/dL • Triglycerides <200mg/dL using 0 or 1 lipid lowering me

  5. Slide 5: Study Design

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP (N=1,267): Morbidly Obese Subjects CONQUER (N=2,487): Obese with Comorbidities Titration (4 weeks) Treatment (52 weeks) EQUIP/CONQUER Treatment Week: Qnexa Full Dose (n=512)/(n=995) Qnexa Low Dose (n=241) EQUIP Placebo (n=514)/(n

  6. Slide 6: EQUIP: Co-Primary Efficacy Endpoints

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com Placebo Qnexa Low Qnexa Full EQUIP: Co-Primary Efficacy Endpoints *p<0.0001 vs. placebo Mean Percent Wt Loss Mean % Weight Loss at Week 56 (ITT-LOCF) n=498 n=234 n=498 -1.6 -5.1 -11.0 -12.0 -9.0 -6.0 -3.0 0.0 * * % Patients Achieving >

  7. Slide 7: EQUIP: Percent Weight Loss by BMI Category (ITT-LOCF)

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP: Percent Weight Loss by BMI Category (ITT-LOCF) 1.8 1.3 1.0 1.1 10.7 11.1 11.2 5.0 5.9 4.3 5.5 11.8 0 2 4 6 8 10 12 >35 - 40 >40 -45 >45 - 50 >50 Placebo Qnexa Low Qnexa Full % Weight Loss Baseline BMI Category *p<0.05 vs. placeb

  8. Slide 8: EQUIP: Continuing Weight Loss Over Time

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP: Continuing Weight Loss Over Time Completers* Lost 14.7% Body Weight - Qnexa Low -7.0%, 18 lbs - Placebo -2.5%, 6 lbs - Qnexa Full -14.7%, 37 lbs Mean % Weight Loss Weeks Patients Placebo Low Full Completers (% of randomized) 241

  9. Slide 9: EQUIP: Significant Categorical Weight Loss with Qnexa Low or Full Dose

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP: Significant Categorical Weight Loss with Qnexa Low or Full Dose 0 10 20 30 40 50 60 70 80 90 5% 10% 15% % of Patients Qnexa Full Qnexa Low PBO % of Patients with: • >15% wt loss PBO 5% Qnexa Low 11%* Qnexa Full 43%** • >10% wt l

  10. Slide 10: EQUIP: Greater Weight Loss Linked to Broader Improvement Across CV Risk Factors

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP: Greater Weight Loss Linked to Broader Improvement Across CV Risk Factors CV Risk Factors (Mean % Wt Loss) Qnexa Low (5.1%) p-value* Qnexa Full (11.0%) p-value* Waist Circumference <0.0001 <0.0001 Systolic BP 0.002 <0.0001 Diasto

  11. Slide 11: OB-303 CONQUER: Effect of Qnexa in Co-Morbid Obese

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com OB-303 CONQUER Effect of Qnexa in Co-Morbid Obese

  12. Slide 12: CONQUER: Co-Primary Efficacy Endpoints

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com -1.8 -8.4 -10.4 -12 -9 -6 -3 0 21 62 70 0 10 20 30 40 50 60 70 80 CONQUER: Co-Primary Efficacy Endpoints *p<0.0001 vs. placebo % of Patients * * Placebo Qnexa Low Qnexa Full Mean % Weight Loss at Week 56 (ITT-LOCF) n=979 n=488 n=981 %

  13. Slide 13: CONQUER: Weight Loss Over Time

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com - Qnexa Mid -10.5%, 24 lbs CONQUER: Weight Loss Over Time Completers* Lost 13.2% Body Weight - Qnexa Full -13.2%, 30 lbs - Placebo 2.4%, 6 lbs Mean % Weight Loss Weeks 42%2 excess body weight loss Patients Placebo Mid Full Completers (

  14. Slide 14: CONQUER: Significant Categorical Weight Loss with Qnexa Mid or Full Dose

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com CONQUER: Significant Categorical Weight Loss with Qnexa Mid or Full Dose 0 10 20 30 40 50 60 70 80 90 5% 10% 15% % of Patients Qnexa Full Qnexa Mid PBO % of Patients with: • >15% wt loss PBO 4% Qnexa Mid 26%** Qnexa Full 39%** • >10% w

  15. Slide 15: CONQUER: Improved Cardiovascular Risk Factors

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com CONQUER: Improved Cardiovascular Risk Factors Risk Factors (Mean % Wt Loss) Qnexa Mid (8.4%) p-value Qnexa Full (10.4%) p-value Waist Circumference <0.0001 <0.0001 Systolic BP <0.0001 <0.0001 Diastolic BP ns 0.0031 Triglycerides <0.000

  16. Slide 16: CONQUER: Decreased BP in Obese Hypertensive Patients

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com -5.6 -8.3 -7.0 -10 -8 -5 -3 0 Placebo Qnexa Mid Qnexa Full 3.4 10.5 6.6 12 10 8 6 4 2 0 2 4 6 Placebo Qnexa Mid Qnexa Full *p=0.0475 vs placebo **p<0.0001 vs. placebo Baseline SBP 135.0 134.0 133.0 SBP (mmHg) ** * SBP Change at Week 56

  17. Slide 17: CONQUER: Improved Diabetes Risk Factors

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com CONQUER: Improved Diabetes Risk Factors Risk Factors Qnexa Mid p-value Qnexa Full p-value Hemoglobin A1c <0.0001 <0.0001 Fasting Blood Glucose 0.0047 <0.0001 OGTT Insulin 0.0007 <0.0001 Insulin Resistance (HOMA) <0.0001 <0.0001 p-value

  18. Slide 18: CONQUER: Decreased HbA1c in Obese Diabetic Patients

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com -0.1 -0.4 -0.4 -0.45 -0.40 -0.35 -0.30 -0.25 -0.20 -0.15 -0.10 -0.05 0.00 Placebo Qnexa Mid Qnexa Full 12.1 0.6 1.5 0 2 4 6 8 10 12 14 Placebo Qnexa Mid Qnexa Full CONQUER: Decreased HbA1c in Obese Diabetic Patients • Rates of hypoglyc

  19. Slide 19: EQUIP & CONQUER Safety and Tolerability

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER Safety and Tolerability

  20. Slide 20: EQUIP & CONQUER: Adverse Events >5%

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Adverse Events >5% EQUIP (N=1,264) CONQUER (N=2,485) % of Patients Placebo Qnexa Low Qnexa Full Placebo Qnexa Mid Qnexa Full Dry Mouth 3.7 6.7 17.0 2.4 13.5 20.8 Tingling 1.9 4.2 18.8 2.0 13.7 20.5 Constipation 6.8 7.9

  21. Slide 21: Discontinuation Rate in All Doses Studied

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com Discontinuation Rate in All Doses Studied Placebo Qnexa Low Qnexa Mid Qnexa Full Number of Subjects 1,508 241 498 1,507 Study Completion 53% 57% 69% 62% Discontinuation due to AEs 9% 12% 12% 18% Blurred Vision 0.5% 2.1% 0.8% 0.7% Heada

  22. Slide 22: EQUIP & CONQUER: Depression Assessment

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Depression Assessment Placebo Qnexa Low Qnexa Mid Qnexa Full Moderate or severe AEs of Depression/Depressed Mood 1.7% 1.7% 1.2% 1.9% • 26-30% of patients had a history of psychiatric disorders at baseline • No serious

  23. Slide 23: EQUIP & CONQUER: Suicidality Assessments

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Suicidality Assessments 0.0% 0.0% 0.0% 0.0% 0.0% Ideation (with intent) Placebo N=1,506 Qnexa Low N=240 Qnexa Mid N=498 Qnexa Full N=1,505 Qnexa All Doses N=2,243 C-SSRS C-SSRS Composite 0.0% 0.0% 0.0% 0.0% 0.0% Suicid

  24. Slide 24: EQUIP & CONQUER: Discontinuation for Cognitive Events

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Discontinuation for Cognitive Events 0.3% 0.0% 0.0% 0.2% 0.0% 0.0% Aphasia (word finding difficulties) EQUIP (N=1,264) CONQUER (N=2,485) % of Patients Placebo Qnexa Low Qnexa Full Placebo Qnexa Mid Qnexa Full Disturban

  25. Slide 25: EQUIP & CONQUER: Serious Adverse Events Attributed to Study Drug by Investigator

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER : Serious Adverse Events Attributed to Study Drug by Investigator Placebo (n=1,508) Qnexa (n=2,243) Rate of SAEs 0.4% 0.4% Description Chest Pain Cholelithiasis Gastric Ulcer Pulmonary Embolism Syncope Uncontrolled Hype

  26. Slide 26: EQUIP & CONQUER: Effects on Blood Pressure & Heart Rate

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com EQUIP & CONQUER: Effects on Blood Pressure & Heart Rate EQUIP (OB-302) CONQUER (OB-303) Placebo Qnexa Low Qnexa Full Placebo Qnexa Mid Qnexa Full Change in Systolic BP at wk 56 (mmHg)* -0.1 -0.9 -2.1 -3.1 -5.2 -5.6 Change in Diastolic

  27. Slide 27: Qnexa Summary

    Copyright © 2009 VIVUS Inc. All rights reserved. | www.vivus.com Qnexa Summary • Unprecedented weight loss 14.7% (37 lbs) • Clinically meaningful improvements across cardiovascular and metabolic risk factors in ITT population • Low, Mid and Full doses of Qnexa exceeded FDA efficacy benchmarks for we

VIVUS — Technical Presentation (October 2009) on 6ix